Pharsight Corporation (PHST) to Work with Critical Path Institute’s Polycystic Kidney Disease Consortium on Disease Progression Modeling  
9/7/2011 10:39:39 AM

ST. LOUIS--(BUSINESS WIRE)--Pharsight, a market-leading provider of software and scientific consulting services to improve productivity and decision-making in clinical drug development, has announced they will be working with Critical Path Institute (C-Path)’s Polycystic Kidney Disease (PKD) Consortium to create and study quantitative models of disease progression in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD).